TEC: Evidence Based Therapeutics
Therapeutics Education Collaboration
Medication Mythbusters – Home of the Best Science (BS) Medicine Podcast


Useful Material for “How to Critically Appraise an RCT in 10 minutes”

FREE ibook version – interactive plus audio

pdf version

Some of the articles we have published in the area of rational therapeutics

  1. McCormack JP, Rangno RE. An evaluation and critique of the use of lipid-lowering drugs in a population base of 400,000 patients over the age of 65. Can J Clin Pharmacol 1994;1(1):27-32
  2. McCormack JP, Rangno RE. Cholesterol lowering in the elderly Can J Clin Pharmacol 1994;1(2):51-2 (Letter)
  3. McCormack JP, Rangno RE. Cholesterol lowering in the elderly Can J Clin Pharmacol 1994;1(3):99-100 (Letter)
  4. McCormack JP, Rangno RE. Dose Titration: Minimize to Maximize. Therapeutics Letter (www.ti.ubc.ca). October 1995;10:1-2
  5. McCormack JP, Rangno RE, Wright J. Evidence Based Drug Therapy: What Do the Numbers Mean? Therapeutics Letter (www.ti.ubc.ca). August/September/October 1996;15:1-4
  6. McCormack JP, Levine M, Rangno RE. Primary prevention of heart disease and stroke: a simplified approach to estimating risk of events and making drug treatment decisions. Can Med Assoc J 1997;157:422-8
  7. McCormack JP, Cooper, J. Carleton B. Simple approach to dosage adjustment in patients with renal disease. Amer J Health Syst Pharm 1997;54:2505-9
  8. Bass F, McCormack JP. Effective clinical tobacco intervention. Therapeutics Letter. (www.ti.ubc.ca). September -October 1997;21:1-4
  9. McCormack JP, Carleton B. A simpler approach to pharmacokinetic dosage adjustments. Pharmacotherapy 1997;17:1349-51
  10. McCormack JP, Loewen P. Treatment of acute migraine headaches. Therapeutics Letter. (www.ti.ubc.ca). November-December 1997;22:1-4
  11. McCormack JP, Levine M, Rangno RE. Patients offered treatment for CHD need full information to make decision. BMJ 1998; 316: 1021-2 (Letter)
  12. Maclure M, Dormuth C, Naumann T, McCormack J, Rangno R, Whiteside C, Wright JM. Influences of educational interventions and adverse news about calcium channel blockers on first-line prescribing of antihypertensive drugs to elderly people in British Columbia. Lancet 1998; 352: 943?48
  13. McCormack JP, Bassett K. The evidence for insulin lispro. Can Med Assoc J. 1998;159:1353 (Letter)
  14. McCormack JP, Levine M, Rangno RE. An easier approach to estimating risk of coronary heart disease and stroke. Circulation 1999;99:2219 (Letter)
  15. McCormack JP, Bassett K. The evidence for insulin lispro. Letter to the Editor. Can Med Assoc J. 1999;160:1551 (Letter)
  16. McCormack JP, Bassett K. Celecoxib (Celebrex®) Is it a Breakthrough Drug? Therapeutics Letter. (www.ti.ubc.ca) August-September 1999;31:1-2
  17. McCormack JP, Greenhalgh T. Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. BMJ 2000;320:1720-3
  18. McCormack JP, Greenhalgh T. Seeing what you want to see in randomised controlled trials – Author’s reply. BMJ 2000;321:1078 (Letter)
  19. McCormack JP. An emotional-based medicine approach to monitoring once-daily aminoglycosides. Pharmacotherapy. 2000;20:1524-7
  20. McCormack JP, Greenhalgh T. Seeing what you https://therapeuticseducation.org/node/18087/edit#want to see in randomised controlled trials: versions and perversions of UKPDS data. WJM 2001; 174:123-127 (a slightly adapted version of above BMJ article)
  21. McCormack JP. Absolute vs. relative numbers in evaluating drug therapy. Amer Fam Physician, 2001;63:1913 (Letter)
  22. McCormack JP. Generic vs. brand name drugs: The warfarin debate is wearing thin. J Inform Pharmacother 2001: 6 (Invited editorial)
  23. McGrath AM, Gardner DM, McCormack J. Is home peak expiratory flow monitoring effective for controlling asthma symptoms? J Clin Pharm Ther 2001; 26:311-317
  24. Nair K, Dolovich L, Cassels A, McCormack JP, Levine M, Gray J, Mann K, Burns S. What patients want to know about their medications. Focus group study of patient and clinician perspectives. Can Fam Physician 2002;48:104-10
  25. McCormack J, Perry T, Rangno R, van Breemen C, Wright JM Assessing the quality of clinical practice guidelines Can Med Assoc J 2002;166:168 (letter)
  26. McCormack JP, Rangno RE Digging for data from the cox-2 trials. Can Med Assoc J;166:1649-50, 2002
  27. McCormack JP. ALLHAT – so what. J Informed Pharmacotherapy 2003;12:1
  28. Cassels A, Hughes MA, Cole C, Mintzes B, Lexchin J, McCormack JP. Drugs in the news: How well do Canadian Newspapers report the good, the bad and the ugly of new drugs. Can Med Assoc J 2003;168:1133-7
  29. McCormack JP, Dolovich L, Levine M, Burns S, Nair K, Cassels A. Mann K, Gray J. Providing evidence-based information to patients in general practice and pharmacies: What is the acceptability, usefulness and impact on drug use? Health Expectations 2003:6:281-9
  30. McCormack J, Loewen P, Jewesson P. Why is There No Value in Clinical Practice Guidelines? J Informed Pharmacotherapy 2003;14
  31. Virani A. Drug Daze. How to prevent or manage drug induced cognitive Impairment. Pharmacy Practice. 2003;19:35-47
  32. Carrey N, Virani A. Suicidal ideation reports from pediatric trials for paroxetine and venlafaxine. The Canadian Child Psychiatry Review 2003;12:101-102
  33. Virani A, Crown N. The Impact of a Clinical Pharmacist on Patient and Economic Outcomes in a Child and Adolescent Mental Health Unit. CJHP 2003;56:158-62.
  34. Bauer G, Virani A, Pohar R. Pharmacists get in the depression management loop. Pharmacy Practice 2003;19:D15-17.
  35. Virani A. ADHD: What’s all the Hype? A workbook for pharmacists. Toronto, ON: Apotex 2003.
  36. Virani A. The pharmacists guide to psychiatric disorders in children and adolescents: A continuing education article for pharmacists. Virtual Learning 2003.
  37. Virani A. Evaluating the Pharmacological Treatment of Depression. Psychiatric Times (Suppl.) 2004;(Jul):1-8.
  38. Virani A. Are Antidepressants Safe and Effective in Pediatric Patients? Child and Adolescent Psychiatric Newsletter. 2004;(Jul):1-7
  39. McCormack J, Loewen P, Jewesson P.  Dissemination of results needs to be tracked as well as the funding is. (letter)BMJ 2005;331:456
  40. McCormack JP, Johns K, Tildesley H. Metformin’s contraindications be contraindicated? CMAJ 2005:173:503-4
  41. Virani A. Psychopharmacology Update: Spotlight on Atomoxetine. J Can Acad Child Adolesc Psychiatry. 2005 (14);4:96-8
  42. Virani A. Antidepressants and Suicide in Youth: Weighing the Evidence. Pharmacy Practice. 2005;21(2):30-36
  43. McCormack J. Loewen P. The other side of the bezafibrate infarction prevention trial data.[Comment. Letter] Arch Intern Med. 2005;165:2431-2
  44. Dolovich L, Burns S, Cassels A, Levine M, Nair K, McCormack JP, Mann K, Gray J. Using patient-oriented evidence-based information guides in practice: The family physician and community pharmacist perspective. Drug Information Journal. 2006;40:61-67
  45. Elan C Paluck EC, McCormack JP, Ensom MHH, Levine M, Soon JA, Fielding DW. Outcomes of bupropion therapy for smoking cessation during routine clinical use. Ann Pharmacother 2006;40: 185-90
  46. Pidsosny I, Virani A. Pediatric Psychopharmacology Update: Psychostimulants and Tics – Past, Present and Future. J Can Acad Child Adolesc Psychiatry. 2006;15(2):84-6
  47. McCormack JP, Loewen P. Adding “value” to clinical practice guidelines. Can Fam Physician 2007;53:1327-35
  48. McCormack JP. Do ß-blockers have a role in treating hypertension?: NO Can Fam Physician 2007;53:614-7
  49. Wright J, McCormack JP. Mild Hypertension – An approach to using evidence in the decision making process. Therapeutics Letter. (www.ti.ubc.ca) 2007;62:1-2
  50. McCormack JP, Wright J. Using Framingham for primary prevention cardiovascular risk assessmentTherapeutics Letter. (www.ti.ubc.ca) 2007 63:1-2
  51. Jureidini J, Perry TL jr, Virani A, Mintzes B, Wright JM. What is the evidence for using CNS Stimulants to treat ADHD in Children. (www.ti.ubc.ca) 2008;69:1-2
  52. McCormack JP. Allan GM. Measuring hsCRP – An important part of a Comprehensive Risk Profile or a Completely  Redundant Practice? PLOS Medicine2010,7: e1000196. doi:10.1371/journal.pmed.1000196
  53. Allan GM, Ivers N, Pimlott N.  Introducing Tools for Practice. Can Fam Physician. 2010; 56(7): 663.
  54. Allan GM, Ivers N, McCormack J.  Type 2 diabetes and ASA. Can Fam Physician. 2010; 56(7):664.
  55. Allan GM, Ivers N, Shevchuk Y.  Treatment of Pediatric Fever: Are acetaminophen and ibuprofen equivalent?  Can Fam Physician. 2010;56(8):773.
  56. Klein D, Allan GM, Manca D, Korownyk C. Research interest group demonstrates effects of collaboration. Can Fam Physician. 2010; 56(8): 830-1.
  57. Allan GM, Korownyk C, LaSalle K, Vandermeer B, Ma V, Klein D, Manca D. Do Randomized Controlled Trials Discuss Healthcare Costs? PLoS ONE 2010; 5(8): e12318. doi:10.1371/journal.pone.0012318
  58. Korownyk C, Allan GM.  Motivating patients to activity – A light at the end of the couch?  Can Fam Physician. 2010;56(9): 887.
  59. Allan GM, Ivers N.  The Autism and Vaccine Story: Fiction and Deception?  Can Fam Physician. 2010;56(10):1013.
  60. McCormack JP. Allan GM. Measuring hsCRP – An important part of a Comprehensive Risk Profile or a Completely  Redundant Practice? PLOS Medicine 2010,7: e1000196. doi:10.1371/journal.pmed.1000196
  61. McCormack JP, Allan GM, Virani AS.  Is Bigger Better?  An argument for “very” low initial doses. CMAJ 2010 Oct 4 [Epub ahead of print].
  62. McCormack JP. Point/Counterpoint. Should all elderly women receive bisphosphonates to prevent osteoporotic fractures? NO. CJHP 2012;65:47-8
  63. Korownyk C, Allan GM, McCormack J. Bioidentical hormone micronized progesterone. Can Fam Physician 2012;58:755
  64. McCormack JP. Allan GM. A prescription for improved antibiotic prescribing in primary care. BMJ 2012;344:d7955
  65. Arroll B, Allan GM, Elley CR, Kenealy T, McCormack J, Hudson B, Hoare K Diagnosis in primary care: probabilistic reasoning. J Prim Health Care 2012;4:166-73.
  66. Korownyk C, Allan GM, McCormack J. Response – Bioidentical hormone therapy. Can Fam Physician 2012;58:1334
  67. McCormack JP. No evidence base for monitoring aminoglycoside levels. BMJ 2012;345:e7264
  68. McCormack JP. Vandermeer B, Allan GM. How confidence intervals become confusion intervals. BMC Medical Research Methodology 2013;13:134  doi:10.1186/1471-2288-13-134
  69. Allan GM, Nouri F, Korownyk C, Kolber MR, Vandermeer B, McCormack J. Agreement among cardiovascular disease risk calculators. Circulation 2013;127:1948-56
  70. McCormack J, Banh HL, Allan GM. Refining the American guidelines for prevention of cardiovascular disease. Lancet 2014;9917:598-9
  71. Lindblad AJ, Garrison S, McCormack J. Testing vitamin D levels.  Can Fam Phys 2014;60:351
  72. Allan GM, Garrison S, McCormack J. Comparison of cardiovascular disease risk calculators. Curr Opin Lipidol 2014;25:254-65
  73. Martin SA, McCormack JP, Newman DH. Letter – Changes in Diabetes-Related Complications in the United States. N Engl J Med 2014;371:284
  74. McCormack JP, Chmelicek JT. Generic versus brand name: the other drug war. Can Fam Phys October 2014 60: 911
  75. Korownyk C, Kolber MR, McCormack J, Lam V, Overbo K, Cotton C, Finley C, Turgeon RD, Garrison S, Lindblad AJ, Banh HL, Campbell-Scherer D, Vandermeer B, Allan GM. Televised medical talk shows-what they recommend and the evidence to support their recommendations: a prospective observational study. BMJ 2014 Dec 17;349:g7346. doi: 10.1136/bmj.g7346.
  76. Caulfield T, Clark MI, McCormack JP, Rachul C, Field CJ. Representations of the health value of vitamin D supplementation in newspapers: media content analysis. BMJ Open 2014;4:e006395 doi:10.1136/bmjopen-2014-006395\
  77. McCormack JP, Martin SA, Newman DH. Comment on Inzucchi et al – Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Diabetes Care 2015;38:e141–e142 | DOI: 10.2337/dc15-0074
  78. McCormack J, Malhotra A, Newman D. Challenging treatment thresholds. Prescriber 2015;5:5-7
  79. Allan GM, Nouri F, Korownyk C, Kolber MR, Vandermeer B, McCormack J. Variation among cardiovascular risk calculators in relative risk increases with identical risk factor increases. BMC Research Notes 2015;8:417
  80. Lehman R, Tejani AM, McCormack J, Perry T, Yudkin JS. Ten Commandments for patient-centred treatment. British Journal of General Practice 2015;65:532-3
  81. Allan GM, Lindblad AJ, Comeau A, Coppola J, Hudson B, Mannarino M, McMinis C, Padwal R, Schelstraete C, Zarnke K, Garrison S, Cotton C, Korownyk C, McCormack J, Nickel S, Kolber MR. Simplified lipid guidelines: Prevention and management of cardiovascular disease in primary care. Can Fam Phy 2015;61:857-67
  82. McCormack J, Malhotra A, Newman D. It’s Time for Shared Decision Making in Cardiovascular Risk Factor Modification. Cardiol Pharmacol 2015;4:3-4
  83. Allan GM, Cranston L, Lindblad A, McCormack J, Kolber MR, Garrison S, Korownyk C. Vitamin D: A Narrative Review Examining the Evidence for Ten Beliefs. J Gen Int Med 2016;31:780-91
  84. Lesser LI, McCormack JP. Financial incentives and cholesterol levels. JAMA 2016;315:1657-8
  85. Yudkin JS, Kavanagh J, McCormack JP. Guidelines for treating risk factors should include tools for shared decision making. BMJ 2016;353:i3147 1-3
  86. Loewen P. Gerber P, McCormack J, MacDonald G. Design and implementation of an integrated medication management curriculum in an entry-to-practice Doctor of Pharmacy Programme. Pharmacy Education 2016;16:122-3
  87. McCormack JP, McAlister FA, Kolber MR. Higher medication doses in heart failure. Can Fam Phy 2017;63:e20
  88. Allan GM, Finley CR, McCormack J, Kumar V, Kwong S, Braschi E, Korownyk C, Kolber MR, Lindblad AJ, Babenko O, Garrison S. Are potentially clinically meaningful benefits misinterpreted in cardiovascular randomized trials? A systematic examination of statistical significance, clinical significance, and authors’ conclusions. BMC Medicine 2017;15:58-68
  89. Allan GM, McCormack J, Korownyk C, Lindblad AJ, Garrison S, Kolber MR. The future of guidelines: Primary care focused, patient oriented, evidence based and simplified. Maturitas 2017:95:61–2
  90. McCracken R, McCormack J, McGregor MJ, Wong S T, Garrison S. Associations between polypharmacy and treatment intensity for hypertension and diabetes: a cross-sectional study of nursing home patients in British Columbia, Canada BMJ Open 2017;7:e017430. doi: 10.1136/bmjopen-2017-017430
  91. Korownyk C, McCormack J, Kolber MR, Garrison S, Allan GM. Competing demands and opportunities in primary care. Canadian Family Physician 2017;63:664-8
  92. Allan GM, Korownyk C, Kolber MR, Garrison S, McCormack J Nickel S, Lindblad A. What’s in your stocking? Evidence around Santa Claus. Canadian Family Physician 2017;63:94
  93. Allan GM, Ramji J, Perry D, Ton J, Beahm NP, Crisp N, Dockrill B, Dubin RE, Findlay T, Kirkwood J, Fleming M, Makus K, Zhu X, Korownyk C, Kolber MR, McCormack J, Nickel S, Noël G, Lindblad AJ. Simplified guideline for prescribing medical cannabinoids in primary care. Can Fam Physician 2018;64:00-0
  94. McCormack JP, Korownyk C. Effectiveness of antidepressants – Invited Editorial. BMJ 2018;360:k1073 doi: 10.1136/bmj.k1073 (Published 9 March 2018)
  95. McCormack JP. Shared decision making and high blood pressure (letter). CPJ – April 2, 2018 https://doi.org/10.1177/1715163518767941
  96. McCormack J, Elwyn G. Shared decision is the only outcome that matters when it comes to evaluating evidence-based practice. BMJ Evidence-Based Medicine 2018;23:137-9
  97. Turgeon RD, Kolber MR, Loewen P, Ellis U, McCormack JP. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis. PLOS 2019 – https://doi.org/10.1371/journal.pone.0212907
  98. McCormack J. Is there adequate evidence for quadrupling inhaled corticosteroid doses? Can Fam Physician. 2019;65: 313-4
  99. McCormack JP, Holmes D. Your results may vary: a precise discussion about the imprecision of medical measurements. BMJ 2020;368 doi: https://doi.org/10.1136/bmj.m149 BMJ COVER STORY\
  100. McCormack JP, Holmes D. Your results may vary – a tool for visualizing the variability of lab test results. BMJ 2020;368:m149
  101. McCormack JP, Brownlee S, Garber J, Devlin J. The endurance of medication overload: Rethinking the medication review process. JACCP 2020;3:396-7
  102. Ton J, Perry D, Thomas B, Allan GM, Lindblad AJ, McCormack J, Kolber MR, Garrison S, Moe S, Craig R, Dugré N, Chan K, Finley CR, Ting R, Korownyk CS. PEER umbrella systematic review of systematic reviews – Management of osteoarthritis in primary care Canadian Family Physician 2020;66:e89-e98
  103. Lindblad AJ, McCormack J, Korownyk CS, Kolber MR, Ton J, Perry D, Thomas B, Moe S, Garrison S, Dugré N, Chan K, Allan GM. PEER simplified decision aid: osteoarthritis treatment options in primary care. Canadian Family Physician 2020;66:191-3
  104. McCormack J, Lindblad. Is hydroxychloroquine (with or without azithromycin) effective in treating COVID-19? Tools for Practice ACFP/CFPC 2020
  105. Allan GM, McCormack J. Are there tools to help assess dyspnea virtually? Tools for Practice ACFP/CFPC 2020
  106. Allan GM, McCormack JP, Kolber MR, Lindblad AJ, Garrison S, Korownyk C. Empowering primary care: PEER’s journey through evidence, transparency, and independence. BMJ 2020 – IN PRESS
  107. Allan GM, McCormack J, Kolber MR, Ton J, Lindblad AJ, Korownyk CS. Misleading communication aid Response Can Fam Physician 2020;66:393-6
  108. Dugre N, Ton J, Perry D, Garrison S, Falk J, McCormack J, Moe S, Korownyk CS. Lindblad AJ, Kolber MR, Thomas B, Train A, Allan GM. Masks for prevention of viral respiratory infections among health care workers and the public. PEER umbrella systematic review. Can Fam Physician 2020;66:509-17
  109. Moe S, Dugré N, Allan GM, Korownyk CS, Kolber MR, Lindblad AJ, Garrison S, Falk J, Ton J, Perry D, Thomas B, Train A, McCormack J. PEER simplified tool: mask use by the general public and by health care workers. Can Fam Physician 2020; 66:505-7
  110. Korownyk C, Allan GM, Dugré N, Lindblad AJ, McCormack J, Kolber MR. Rapid review of COVID-19. Can Fam Physician. 2020;66:429
  111. McCormack J, Dugre N, Moe S, Korownyk C, Kolber MR, Allan GM. Clear and consistent message about masks. Response. Can Fam Physician 2020;66:636-7
  112. Sadatsafavi M, McCormack J, Petkau J, Lynd LD, Lee TY, Sin DD. Should the number of acute exacerbations in the previous year be used to guide treatments in COPD. European Respiratory Journal Jan 2020, 2002122; DOI: 10.1183/13993003.02122-2020
  113. Blom J, Muth C, Glasziou P, McCormack J, Perera R, Poortvliet R, Numans M, Thürmann P, Thiem U, Thio S, Van Driel M, Beyer M, Van den Akker M, Knottnerus J, Describing deprescribing trials better: an elaboration of the CONSORT statement, Journal of Clinical Epidemiology 2020, doi: https://doi.org/10.1016/j.jclinepi.2020.07.011
  114. Korownyk CS, McCormack J, Lindblad AJ, Garrison S, Kolber MR, Allan GM. Re: Efficacy and safety of antidepressants for the treatment of back pain and osteoarthritis: systematic review and meta-analysis. BMJ 2021. Letter to the Editor Jan 30, 2021
  115. Kolber MR, Ton J, Thomas B, Kirkwood J, Moe S, Dugré N, Chan K, Lindblad AJ, McCormack J, Garrison S, Allan GM, Korownyk CS, Craig R, Sept L, Rouble AN, Perry D. PEER systematic review of randomized controlled trials. Management of chronic low back pain in primary care. Can Fam Phys 2021;67 (1) e20-e30; DOI: 10.46747/cfp.6701e20
  116. Kirkwood J, Allan GM, Korownyk CS, McCormack J, Garrison S, Thomas B, Ton J, Perry D, Kolber MR, Dugré N, Moe S, Lindblad AJ. PEER simplified decision aid: chronic back pain treatment options in primary care. Can Fam Phys 2021;67 (1) 31-34; DOI: https://doi.org/10.46747/cfp.670131
  117. Falk J, Thomas B, Kirkwood J, Korownyk CS, Lindblad AJ, Ton J, Moe S, Allan GM, McCormack J, Garrison S, Dugre N, Chan K, Kolber MR, Train A, Froentjes L, Sept L, Wollin M, Craig R, Perry D. PEER systematic review of randomized controlled trials. Management of chronic neuropathic pain in primary care. Canadian Family Physician May 2021, 67 (5) e130-e140; DOI: https://doi.org/10.46747/cfp.6705e130
  118. Chan K, Perry D, Lindblad AJ, Garrison S, Falk J, McCormack J, Korownyk CS, Kirkwood J, Ton J, Thomas B, Moe S, Dugré N, Kolber MR, Allan GM. PEER simplified decision aid: neuropathic pain treatment options in primary care. Canadian Family Physician 2021:67:347-9
  119. Saatchi A, Morris AM, Patrick DM, McCormack J, Reyes RC, Morehouse P, Reid J, Shariff S, Povitz M, Silverman M, Marra F. Outpatient antibiotic use in British Columbia, Canada: reviewing major trends since 2000. JAC-Antimicrobial Resistance, 2021;3,https://doi.org/10.1093/jacamr/dlab116
  120. Korownyk CS, Allan GM, McCormack J, Lindblad AJ, Horvey S, Kolber MR. Successes, lessons and opportunities: 15-year follow-up of an integrated evidence-based medicine curriculum. BMJ Evidence-Based Medicine 2021. doi: 10.1136/bmjebm-2020-111393
  121. Garrison S, McCormack J. Blood pressure: how low should it go? Lancet 2021;398:1684 https://doi.org/10.1016/S0140-6736(21)01857-2
  122. Saatchi A, Yoo J-W, Schwartz KL, Silverman M, Morris AM, Patrick DM, McCormack J, Marra F. Quantifying the Gap between Expected and Actual Rates of Antibiotic Prescribing in British Columbia, Canada. Antibiotics. 2021; 10(11):1428. https://doi.org/10.3390/antibiotics10111428
  123. Mangin D, Lamarche L, Agarwal G, Banh HL, Dore Brown N, Cassels A, et al. Team approach to polypharmacy evaluation and reduction: study protocol for a randomized controlled trial. Trials. 2021 Oct 26;22(1):746.
  124. Saatchi A, Yoo JW, Schwartz KL, Silverman M, Morris AM, Patrick DM, McCormack J, Marra F. Quantifying the Gap between Expected and Actual Rates of Antibiotic Prescribing in British Columbia, Canada. Antibiotics 2021, 10(11), 1428; https://doi.org/10.3390/antibiotics10111428
  125. Garrison SR, Kolber MR, Allan GM, McCormack J, et al Bedtime versus morning use of antihypertensives for cardiovascular risk reduction (BedMed): protocol for a prospective, randomised, open-label, blinded end-point pragmatic trial BMJ Open 2022;12:e059711. doi: 10.1136/bmjopen-2021-05971
  126. Korownyk CS, Montgomery L, Young J, Moore S, Singer AG, MacDougall P, Darling S, Ellis K, Myers J, Rochford C, Taillefer M, Allan GM, Perry D, Moe SS, Ton J, Kolber MR, Kirkwood J, Thomas B, Garrison S, McCormack JP, Falk J, Dugré N, Sept L, Turgeon RD, Paige A, Potter J, Nickonchuk T, Train AD, Weresch J, Chan K, Lindblad AJ. Canadian Family Physician March 2022, 68 (3) 179-190; DOI: https://doi.org/10.46747/cfp.6803179

Books/chapters we have published in the area of rational therapeutics

  1. Editor: Gray J. Associate Editors: Gillis A, Johnson G, Johnson J, MacLeod S, Matsui D, McCormack J, Patterson C, Rangno R, Richardson J. Therapeutic Choices – 1st to 4th edition. Canadian Pharmaceutical Association
  2. Editor: McCormack JP. Associate Editors: Brown G, Rangno R, Levine M, Ruedy J. Drug Therapy Decision Making Guide.Philadelphia:WB Saunders 1996 (550 pages)
  3. Virani AS. ADHD, in Therapeutics Choices, Fifth Edition. Canadian Pharmacists Association Publishers, 2007.
  4. Bezchlibnyk-Butler K, Virani AS. Clinical handbook of psychotropic drugs for children and adolescents, Second Edition. Cambridge, MA: Hogrefe & Huber Publishers, 2004 and 2007. (346 pp) http://www.hhpub.com/index.html (ISBN 978-0-88937-309-9)
  5. McCormack J, Gray M. The Nutrition Proposition. Self-published on Amazon. 2022 (426 pages)



BS Medicine Podcast

The 2024 MEME Conference – May 24-25, 2024


Making Evidence Matter For Everyone | May 24 & 25, 2024
From the clinicians who brought you the Best Science Medicine Course and the Meds Conference, as well as the BS Medicine Podcast and Tools for Practice




Check it out at nutritionproposition.com and think about picking up a copy on Amazon. All the evidence you ever wanted about nutrition and the only nutrition book that won’t tell you what to eat.


BedMed: The High Blood Pressure Study

This pragmatic trial is now recruiting in BC. Make a difference and get involved with pragmatic trials (www.pragmatictrials.ca)

PEER Tools


Recent Posts